MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.

En condiciones normales, la hormona insulina controla el manejo de la glucosa para utilizarse ... En ayunas de 8 horas sin ...

Objective: Despite the demonstrated benefits of glycemic control, patient acceptance of basal/bolus insulin therapy for type 1 diabetes has been slow. We investigated whether a basal/bolus insulin ...

compared the efficacy and safety of a basal-bolus insulin regimen with that of sliding-scale regular insulin (SSI) in hospitalized general medical patients with type 2 diabetes. The prospective ...

Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...

Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE, ...

Lejos de quedarse callado, la mañana de este viernes, de Brito dio a conocer un informe que redactaron los médicos del Hospital Italiano a pedido de la jueza, quien mediará entre Elba Marcovecchio, la ...

Of the 419 subjects screened, 328 were randomized to a treatment group. In the inhaled insulin group, 1 subject allocated to inhaled insulin was never treated; thus, 327 subjects received the ...